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Abstract
Background: Acupuncture is widely-used to treat patients with low back pain, despite insufficient evidence of the
technique’s efficacy for acute back pain. Motion style acupuncture treatment (MSAT) is a non-traditional
acupuncture treatment requiring a patient to exercise while receiving acupuncture. In Korea, MSAT is used to
reduce musculoskeletal pain and improve functional status. The study aims to evaluate the effect of MSAT on
acute low back pain with severe disability.
Methods/Design: This study is a multicenter, randomized, active-controlled trial with two parallel arms. Participants
with acute low back pain and severe functional disability, defined as an Oswestry Disability Index (ODI) value >
60%, will be randomly allocated to the acupuncture group and the nonsteroidal anti-inflammatory drug (NSAID)
injection group. The acupuncture group will receive MSAT and the NSAID injection group will receive an
intramuscular injection of diclofenac. All procedures will be limited to one session and the symptoms before and
after treatment will be measured by assessors blinded to treatment allocation. The primary outcome will be
measured at 30 minutes after treatment using the numerical rating scale (NRS) of low back pain while the patient
is moving. Secondary outcomes will be measured at 30 minutes after treatment using the NRS of leg pain, ODI,
patient global impression of change, range of motion (ROM) of the lumbar spine, and degrees of straight leg
raising (SLR). Post-treatment follow-up will be performed to measure primary and secondary outcomes with the
exception of ROM and SLR at 2, 4, and 24 weeks after treatment.
Discussion: The results of this trial will be discussed.
Trial Registration: ClinicalTrial.gov NCT01315561
Background
Low back pain is a common symptom that greatly
impacts individuals and societies and is experienced by
70-80% of adults at least once in their lives [1]. Approxi-
mately $26.3 billion was spent due to low back pain in
the United States in 1998 [2]. Because back pain is
usually a self-limiting and benign condition, patients
who experience acute back pain typically see improve-
ments and are able to return to work within a month
[3,4]. However, 2-7% of patients develop chronic back
pain, and 75-85% of absences from work are due to
chronic or recurrent back pain [5,6]. Thus, when acute
back pain occurs, it is important to reduce it using a
treatment with minimal side effects to improve the
patient’s functionality, reduce absences from work, and
prevent the development of chronic back pain [7,8].
The common treatment for low back pain is to pre-
scribe painkillers, such as acetaminophen or nonsteroi-
dal anti-inflammatory drugs (NSAIDs), while
encouraging patients to maintain their daily activities
[9,10]. NSAIDs are effective as a short-term treatment
for back pain, and are superior to acetaminophen for
alleviating pain [11]. Intramuscular application of an
NSAID, most commonly diclofenac, is a treatment for
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any medium, provided the original work is properly cited.acute pain [12]. However, gastrointestinal side effects are
common with NSAID use [13]. In recent years, there
has been growing concern regarding the safety of
cyclooxygenase-2 selective NSAIDs for cardiovascular
diseases, especially thrombotic diseases such as acute
myocardial infarction, instable angina, stroke, and sud-
den death [14].
Acupuncture has been widely-used as a method for
treating back pain, but there has been controversy about
its effects. A systematic review of the literature con-
cluded that acupuncture is effective for pain relief and
functional improvement in chronic back pain in the
short term, but that, for acute back pain, no evidence of
the effectiveness of acupuncture was found [15]. Guide-
lines for low back pain treatment recommend acupunc-
ture only for chronic back pain [9,10]. There are a
variety of ways to administer acupuncture. Motion style
acupuncture treatment (MSAT) is different from tradi-
tional acupuncture treatments, and is often used in
South Korea. Yet, we have not found any clinical trials
examining the effectiveness of MSAT. MSAT is similar
to traditional acupuncture in that a needle is inserted
into an acupuncture point. But, MSAT is novel in that
it requires a part of the patient’s body to move passively
or actively while acupuncture needles are inserted for a
certain period of time.
This study is designed to examine the effects of
MSAT on acute low back pain with severe disabilities.
Methods/Design
Overview
This study is a multicenter, randomized, active-con-
trolled, assessor-blinded trial with two parallel arms.
The trial will be conducted in the following two hospi-
tals after obtaining permission from the Institutional
Review Boards of the two institutions: Jaseng Hospital
of Oriental Medicine in Seoul, Korea and Bucheon
Jaseng Hospital of Oriental Medicine in Bucheon, Korea.
The volunteers will be randomly divided into two
groups (1:1 ratio). The experimental group will receive a
single session of MSAT, and the control group will
receive a single intramuscular injection of NSAIDs to
treat acute low back pain. Thirty minutes after treat-
ment, the subjects will be assessed to determine the out-
come of the treatment. Post-treatment follow-up will be
performed to measure primary and secondary outcomes
at 2, 4, and 24 weeks after treatment (Figure 1).
Recruitment
We will recruit outpatients who come to Jaseng Hospital
of Oriental Medicine in Seoul, Korea and Bucheon
Jaseng Hospital of Oriental Medicine in Bucheon, Korea
due to acute low back pain. If patients are interested in
participating in the study, they will be contacted by a
study researcher to determine eligibility in a pre-screen-
ing. If the applicant is eligible according to the study
criteria, he or she will be examined for eligibility by phy-
sicians. And then a study researcher will obtain written
informed consent from each eligible participant and
administer the baseline questionnaire followed by ran-
dom allocation of the participant.
Eligibility
Inclusion criteria
￿ Patients whose low back pain has persisted for less
than 4 weeks with or without leg pain.
￿ Patients with severe disability, defined as an Oswes-
try Disability Index (ODI) value ≥ 60%.
 
Patient Recruitment 
Group A (n=29) 
Motion Style Acupuncture 
Treatment group 
Group B (n=29) 
NSAID injection group 
Random allocation 
(n=58) 
Screening by Inclusion and Exclusion Criteria 
(n=58) 
Outcome assessment at 30 minutes after treatment 
Treatment, one session 
Outcome assessment at 2, 4 and 24 weeks after 
treatment (Follow-up by phone interview) 
Figure 1 The Flow of Participants.
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Page 2 of 7￿ Patients who are 20 - 60 years of age.
￿ Patients who are able to receive a lumbar magnetic
resonance imaging (MRI) scan and agree to the
procedure.
￿ Patients who agree to voluntarily participate in this
study and sign informed consent.
Exclusion criteria
￿ Patients who have been diagnosed with a serious dis-
ease that can cause low back pain (e.g., cancer, vertebral
fracture, spinal infection, inflammatory spondylitis,
c a u d ae q u i n ac o m p r e s s i o n ,o ro t h e rd i s q u a l i f y i n g
conditions).
￿ Patients with a chronic disease that could interfere
with the effect of the treatment or the interpretation of
treatment results (e.g., cardiovascular disease, diabetic
neuropathy, fibromyalgia, rheumatoid arthritis, demen-
tia, epilepsy, or other disqualifying conditions).
￿ Patients with progressive neurological deficit or
severe neurological symptoms.
￿ Patients for whom acupuncture would be inap-
propriate or unsafe (e.g., hemorrhagic disease, clotting
disorders, a history of receiving anticoagulant therapy,
severe diabetes with a risk of infection, severe cardiovas-
cular disease, or other disqualifying conditions)
￿ Patients currently taking corticosteroids, immuno-
suppressant drugs, psychiatric medicine, or any other
medication that may influence the results.
￿ Patients who had experienced gastrointestinal side
effects after taking NSAIDs or are currently being trea-
ted for gastrointestinal disease.
￿ Patients who are currently pregnant or planning to
become pregnant.
￿ Patients who are judged to be inappropriate for the
clinical study by the researchers.
Sample size
The sample size for this clinical study was estimated
using the mean difference in numerical rating scale
(NRS) for low back pain between the experimental and
control groups. We used the NRS as a scale measuring
the pain intensity of low back pain. As MSAT is more
effective than NSAID injection in previous clinical
experience, we set the effect size (Cohen’s d) > 0.5.
The hypothesis of this study is as follows:
H0 : μt = μc vs.H1 : μt  = μc
μt : the mean difference of NRS of the experimental
group from baseline
μc : the mean difference of NRS of the control group
from baseline
Based on previously published results [16], the mean dif-
ference of NRS of low back pain in the experimental
group from baseline was 3.3, but, as there was no prior
existing information on mean difference for the control
group, we set the mean difference at 1 based on the
experience of a clinical expert. According to these estima-
tions, although the difference between the mean difference
of the two groups is 2.3, we conservatively set it as 2. The
standard deviation between the two groups was estimated
to be 2.5. When a two-tailed test with a test power of 80%
and significance level of 5% was applied to the following
formula [17], the number of subjects required for each
group was 26 people. For a successful study, a total of 58
people, with a 10% dropout rate factored in, is required.
Sample size:
n =
2(zα/2 + z1−β)
2σ2
(μt − μc)
2
n = the number of subjects required in each group
μt - μc =2
s = 2.5
Za/2 = Z0.05/2 = 1.96
Z1-b = Z0.8 = 0.8416
Randomization
Randomization will be conducted by an expert on statis-
tics who will have no contact with the patients. Random
numbers with block randomization will be generated
using the SAS version 9.1.3 statistical package (SAS
Institute, Cary, NC, USA), and a block size of 6 is used
to allocate the two groups (1:1 ratio). The numbers will
be kept by a researcher who has no direct contact with
the study participants. The randomized numbers will be
kept in sealed envelopes, and random allocation will be
conducted by opening an envelope as the researcher is
informed of a participant’s registration at each clinical
trial center. In the case of events deemed necessary to
code break halfway during trial such as serious adverse
events, the researcher will be contacted.
Before the randomization allocation, participants will
be informed that they will be assigned to one of the two
groups. Random allocation will be performed if a parti-
cipant is eligible and signs the informed consent form.
The subject identification codes will be recorded on
case report forms (CRFs) and the randomization table.
Blinding
This study is designed as a randomized, controlled,
assessor-blinded trial. Ast h ee x p e r i m e n t a lg r o u p
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control group receives NSAID injection, we are unable
to blind both physician and subject to the modality of
treatment. Still, assessor-blinding will be achieved by
blinding the assessor performing outcome assessment
and CRF data entry to the random allocation and treat-
ment of subjects. Statistical analysis will be performed
by an independent statistician who is blinded to the
identification of each treatment group.
Treatment protocol
The acupuncture group and the NSAID injection group
will each receive a single treatment session.
Acupuncture group
The acupuncture treatment will be conducted by oriental
medicine doctors who have more than 5 years of clinical
experience. These doctors will be required to complete
three workshop sessions prior to participating in this
study to ensure that the acupuncture is performed as sta-
ted in the protocol (see additional file 1 and 2).
First, an assistant stands on each side of the subject
with their arms around the patient’s shoulders to help
the patient stand up. The assistants stand and hold the
subject’sa r m so nt h e i rs h o u l d e r sw h i l eg e n t l yh o l d i n g
one of the subject’s hands and holding the subject’s
waist as if they were lifting. In this position, the practi-
tioner inserts disposable needles to a depth of 10-15
mm at the subject’s Pungbu (GV16) and on both sides
of Haenggan (LR2) and Gokji (LI11). These acupuncture
points were selected according to traditional Chinese
medicine theory and previous clinical experiences.
When being inserted into GV16 and both sides of LR2,
the needles are positioned perpendicular to the body
surface. For LI11, the needle is positioned 30 degrees to
the body surface. No specific manipulative interventions
will be employed in this process. Disposable sterile nee-
dles (40 mm × 0.25 mm; Dong-bang Acupuncture,
SeongNam, Korea) will be used. Each acupuncture point
will be decided on using guidelines based on the World
Health Organization Standard Acupuncture Point Loca-
tions in the Western Pacific Region [18]. While the nee-
dles are still in place, the subject will be asked to walk
with the support of the assistants. When the subject’s
walking improves and the pain is relieved, the practi-
tioner will instruct the assistants to gradually reduce
their assistance in three stages and to continue walking
with the patient. Once the subject’s walking ability
improves and the pain is relieved, support is reduced
further, and one of the assistants stops supporting the
subject. When the subject is able to walk without feeling
any severe back pain, the other assistant also stops pro-
viding assistance. When the subject is able to walk with-
out a great amount of pain, the treatment is terminated.
The procedure takes up to approximately 20 minutes.
If a subject refuses the treatment due to intolerably
severe pain during the procedure, the procedure is
stopped immediately and the degree of increase in pain
and any abnormal reactions are carefully observed and
recorded. The total number of subjects who terminate
the treatment is recorded.
NSAID injection group
Subjects who are assigned to the control group will
receive an intramuscular injection of diclofenac sodium
(75 mg; KUKJE Pharmaceutical, SeongNam, Korea) in
an area of the buttocks where there is no pain. The pre-
sence of gastrointestinal side effects or any other side
effects will be carefully observed and recorded. In addi-
tion, the number of subjects who receive the treatment
will be recorded.
Outcome measurements
When the patients are screened, they will complete
questionnaires about their sex, age, height, weight, blood
pressure, medical history, and other factors. To deter-
mine whether the subjects qualify for the study, their
ODI will be calculated through a questionnaire. Their
history of back pain, pain intensity, functional status,
and other factors will be surveyed. They will also receive
a physical examination, X-ray, and lumbar MRI. Evalua-
tions of the patients’ back pain will be conducted at
baseline and 30 minutes after treatment (Table 1),
because the pain relief and improvement in motion due
to MSAT appears immediately after the treatment and
the maximum plasma concentration for diclofenac is
about 10-20 minutes after intramuscular injection. We
will also perform additional follow-ups at 2, 4, and 24
weeks and assess the outcome to verify the durability of
our treatment. But, we will use telephone interviews to
make assessment simpler, and range of motion (ROM)
and degree of straight leg raising (SLR) will not be
included as outcome measures at post-treatment follow-
up for that reason. Researchers who are blinded to the
identification of each treatment group and do not parti-
cipate in the acupuncture treatment will perform the
outcome assessment.
Primary outcome measures
Primary outcome refers to the intensity of low back
pain, and it will be evaluated using the NRS. Although
the NRS is considered a subjective evaluation indicator,
it is widely used due to its simplicity. With NRS, a
patient chooses one number, ranging from 0 to 10, that
best expresses their current level of pain (0 being no
pain and 10 being the most excruciating pain the sub-
ject has ever experienced) [19,20]. Because the severity
of pain can differ at rest and during activity, subjects
will be asked this question to reduce errors: “Please
indicate the intensity of pain you feel now as you try to
move.” The NRS for back pain will be obtained at
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24 weeks after treatment.
Secondary outcome measures
The patients’ functional status will be evaluated using
the ODI questionnaire. It is a 10-item questionnaire
developed to evaluate the degrees of disability for lower
back pain [21]. Each category is divided into six stages
with 0-5 points each. A high number of points indicates
severe disability. The accredited Korean version of the
ODI questionnaire [22] will be conducted at baseline
and 30 minutes and at 2, 4, and 24 weeks after
treatment.
To complete a comprehensive evaluation of improve-
ment in back pain and the movement limited by back
pain, we will determine the patient global impression of
change (PGIC) [19,23]. PGIC is a method for patients to
subjectively evaluate their improvement by selecting one
of seven stages: 1, very much improved; 2, much
improved; 3, minimally improved; 4, no change; 5, mini-
mally worse; 6, much worse; or 7, very much worse.
This indicator was originally developed for psychiatry,
but it has also been used in other medical areas to
assess the improvement of pain. The PGIC will be
determined for each patient 30 minutes and 24 weeks
after treatment.
Because this study will be conducted with patients
who have limited movement due to severe pain, we will
check their ROM and degree of SLR to assess the
improvement of their movement at baseline and 30
minutes after treatment. The measurement of ROM is
reliable (r = 0.94) and valid (r = 0.97) [24], but it is not
very responsive (effect size 0.1-0.6) [25]. Also, the mea-
surement of SLR is reliable (intraclass correlation coeffi-
cient = 0.95) [26], and the sensitivity is 0.8 (72-97%), the
specificity is 0.4(11-66%) [27], but it is not very respon-
sive (effect size = 0.2) [25]. As the responsiveness of
ROM and SLR measurement is not high, we decided to
use it as a secondary outcome measure instead of a pri-
mary outcome measure.
The ROM is checked by measuring the angle between
the lumbar spine and a vertical straight line at the
patient’s full extension and flexion capability. If the mea-
surement is impossible because of pain, the angle is
recorded as 0 degrees. To measure degrees of SLR, we
will check the leg angle from the patient in a supine
position who will then lift each leg up passively with
their legs extended. We will measure the angle from the
elevated leg to the surface of the floor.
Patients with low back pain may or may not have
accompanying leg pain. When leg pain is reported, to
assess any improvement in symptoms, the degree of
pain is measured for the left and right sides separately
by using the NRS. The degree of leg pain might also dif-
fer at rest and during activity. Therefore, when the NRS
is being evaluated, patients will be asked to answer the
question, “Please indicate the intensity of pain you feel
now as you are try to move” to minimize errors. The
NRS for leg pain will also be checked at baseline and 30
minutes and at 2, 4, and 24 weeks after treatment.
Statistical analyses
All statistical analyses will be performed in the principle
of intention-to-treat analysis using the SAS version 9.1.3
statistical program. For descriptive statistics, normally
distributed variables will be expressed as mean and stan-
dard deviation. Variables with a skewed distribution or
non-parametric variables will be expressed as median
and range. For the comparison of the NRS, ODI, ROM
and SLR between the two groups, independent t-test
will be used, followed by the calculation of effect size
(Cohen’s d) with 95% confidence interval. If there are
any differences in age, gender and body mass index
between the two groups and the differences are thought
to have any influences on the outcome variables, the
Table 1 Schedule for data collection and outcome measurement.
Measures Baseline 30 minutes 2 week 4 week 24 week
Sociodemographic characteristics ●
History of low back pain ●
X-ray ●
Lumbar MRI ●
NRS for back pain ●● ● ● ●
NRS for leg pain ●● ● ● ●
ODI for functional status ●● ● ● ●
PGIC for global improvement ●●
ROM of lumbar spine ●●
Degrees of SLR ●●
Adverse events ●● ● ●
Abbreviations: MRI, magnetic resonance imaging; NRS, numerical rating scale; ODI, Oswestry disability index; PGIC, patient global impression of change; ROM,
range of motion; SLR, straight leg raising
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and the analysis of covariance (ANCOVA) will be per-
formed. The results will be considered to be statistically
significant when P < 0.05.
All adverse events reported during the study will be
i n c l u d e di nt h eC R F s ;t h ei n c i d e n c eo fa d v e r s ee v e n t s
will be calculated. The percentage of subjects with
adverse events in each group will be calculated and
compared using the Chi-squared test or Fisher’s exact
test.
Data handling
Researchers will enter the collected data into the CRFs;
unclear or out of range entries and omissions will be
recorded on data query forms, which will be returned to
the investigational site for resolution. The data from all
centers will be pooled and summarized with respect to
demographic baseline characteristics, effectiveness, and
safety observations.
Data monitoring
Regular monitoring will be conducted for quality con-
trol. Investigators will also convene regularly to discuss
practical issues that may be encountered, such as deal-
ing with serious adverse events, revising the protocol, as
well as any other important issues raised by the investi-
gators or participants.
Safety monitoring
The assessment of safety will be based mainly on the
frequency of adverse events, which includes all serious
adverse events. Information regarding adverse events
will be summarized by presenting the number and per-
centage of participants that experienced adverse events,
with the information also categorized according to the
body region affected. Any other collected information
(e.g., severity or relevance to treatments) will be
included in the safety monitoring reports.
Stopping rules
The trial will stop if the principle investigator believes
there is an unacceptable risk of serious adverse events
in the groups.
Additional material
Additional file 1: Detailed explanation of method of MSAT. A text
file describing the method, origin, purpose and applications of MSAT.
Additional file 2: Movie file of method of MSAT. A movie file
illustrating the method of MSAT through a demonstration with an actual
patient.
List of abbreviations used
NSAID: nonsteroidal anti-inflammatory drug; MSAT: motion style acupuncture
treatment; ODI: Oswestry Disability Index; MRI: magnetic resonance imaging;
NRS: numerical rating scale; CRF: case report form; ROM: range of motion;
SLR: straight leg raising; PGIC: patient global impression of change.
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